



The European Federation of Allergy and Airways Diseases Patients Associations (EFA)

EFA is a European network of allergy, asthma and COPD patient organisation that was founded in 1991, prompted by the belief that an international organisation formed by European patients' associations that share the same aims would be a more effective way to serve the needs and safeguard the rights of patients and their carers. We have supported this organisation since 1997.

During 2022:

GSK provided £0 of funding

Our support represented (0 %) of their overall income in 2022

During 2021:

GSK provided a total of £70,000:

£70,000 in support of Define Your Asthma 2020 campaign that provided a suite of social media assets for use by member organisations at a local level. The Define Your Asthma project's objective is to educate patients about severe asthma. The work will support patients in their conversations with their healthcare professionals about their symptoms, whilst also supporting patients in having conversations with employers, family, and friends about the impact of their condition.

Our support represented 10.62 % of their overall income.

During 2020:

GSK provided:

30,000 euro in support of corporate partnership, which involved EFA's first online Annual General Meeting of Members (AGM) and 18 calls with the EFA working groups, which helped coordinate World Disease Days and the EFA Allergy and Respiratory Patients' Conference and to define the EFA strategy 2021-2027.

10,000 euro for capacity building which involved o Allergy and Respiratory Patients Digital Conference where several speakers, experts in digitalisation in the healthcare sector, presented and engaged with the public. The aim of this day was to provide patients with trainings, aiming at increasing their digital skills and their confidence in a digital environment. o Meet and Greet the EU event to increase understanding among EFA patient networks about the policies and opportunities. o Targeted training for EFA members

25,000 euro for Show Leadership project that involved: o Adoption of Breathe Vision for 2030, a document that outlines the changes that lung patients want to see in their lives in the coming decade in the areas of Awareness, Prevention, Access, Research, and the Impact of COVID-19, all while working towards a European Health Union. o Adoption of a revised Interest Group strategy 2020-2024. The strategy is based on a vision to engage EU policymakers and stakeholders to trigger evidence-based policy change on allergy and asthma. o Launch of the Allergy & Asthma Youth Parliament to establish a platform for the next generation of health leaders. Their role is to inform European policymakers on how their work can support young people living with asthma and allergies.

3305 euro for attendance at GSK's Patient Advocacy & Advisory Board (PAAB)

Our support represents 8.44% of their overall income.